100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
DEVICE RAC EXAM STUDY GUIDE Questions with 100% Correct Answers Latest Version 2024 Verified $8.99   Add to cart

Exam (elaborations)

DEVICE RAC EXAM STUDY GUIDE Questions with 100% Correct Answers Latest Version 2024 Verified

 0 view  0 purchase
  • Course
  • Institution

DEVICE RAC EXAM STUDY GUIDE Questions with 100% Correct Answers | Latest Version 2024 | Verified 510(k) Premarket Notifications for all of the following medical devices would be reviewed by CDRH's Office of Device Evaluation except: A) High Flux Hemodialyzer B) Blood specimen collection devic...

[Show more]

Preview 4 out of 36  pages

  • June 20, 2024
  • 36
  • 2023/2024
  • Exam (elaborations)
  • Questions & answers
avatar-seller
DEVICE RAC EXAM STUDY GUIDE
Questions with 100% Correct Answers |
Latest Version 2024 | Verified
510(k) Premarket Notifications for all of the following medical devices would be reviewed by CDRH's
Office of Device Evaluation except:



A) High Flux Hemodialyzer

B) Blood specimen collection device

C) Piston syringe

D) Cardiopulmonary bypass blood tubing - ✔✔B



A 510(k) submission for any Class III device MUST include:

A. Clinical results summary

B. Hazards analysis evaluation

C. Stability evaluation

D. Certification and summary - ✔✔D



A clinical study sponsor's representative conducts periodic monitoring site visits for all of the following
purposes EXCEPT to:

A. Review raw data

B. Ensure compliance with the protocol

C. Review the protocol with the investigator

D. Ensure the adequacy of the IRB and its procedures - ✔✔D



A company has been given a product from its British subsidiary to market for the first time in the US. The
product is marketed in the EU. A project team gathered by the regulatory professional to review the
information available for regulatory submission to FDA should:

A. Focus on labeling and marketing since mutual recognition does not require complete technical review

,B. Include production, marketing, QA and clinical research for a thorough review

C. Summarize financial data and distribution data which are normally required to be submitted to FDA

D. Not be necessary if a Common Technical Document has been prepared by the subsidiary - ✔✔B



A company has found a way to produce its drug product more economically; however, the current
manufacturing process would have to be changed substantially. What would be the most appropriate
post-approval vehicle for this potential action?

A. Post-Approval Supplement: Changes Being Effected - Immediate (CBE 0)

B. Post-Approval Supplement: Changes Being Effected in 30 Days (CBE 30)

C. Prior approval supplement

D. Annual report - ✔✔C



A company has received a 10-page FDA-483. The regulatory affairs professional's supervisor has
prepared a detailed response assuring the FDA district office that corrective action has been taken for
each observation. Which of the following should be done?

A. Re-audit the company's corrective actions before the letter is sent

B. Re-audit the company's corrective actions within three months because FDA usually conducts

C. Re-audit the company's corrective actions during the next scheduled audit

D. Re-audit the company's corrective actions immediately after the letter is sent - ✔✔A



A company is using a clinical research organization (CR0) to develop the protocol and monitor the clinical
investigators for the company's clinical trial. The regulatory affairs professional may interact with the CR0
in which of the following situations?

A. Making presentations to the reviewing IRBs

B. Making presentations to the reviewing division at FDA

C. Witnessing the signing of patient consent forms

D. Arranging for FDA investigators to observe treatment of subjects at clinical sites - ✔✔B



A company wants to modify its device such that there is a major change to the fundamental scientific
technology of the device. The FDA has published a guidance on this technology and special controls have
been established. This change would be best filed as a(n):

,A. Special 510(k)

B. Abbreviated 510(k)

C. Traditional 510(k)

D. PMA - ✔✔B



A company wants to modify its device such that there is a major change to the fundamental scientific
technology of the device. The FDA has published a guidance on this technology and special controls have
been established. This change would be best filed as a(n):

A. Special 510(k)

B. Abbreviated 510(k)

C. Traditional 510(k)

D. PMA - ✔✔B?



A company wants to modify its legally marketed device such that the modification does not affect the
intended use or alter the fundamental scientific technology of the device. If the design outputs of the
modified device meet the design input requirements, this change would be best filed as a(n):

A. Special 510(k)

B. Abbreviated 510(k)

C. Traditional 510(k)

D. De novo 510(k) - ✔✔A



A company's competitor is marketing a Class II suture which dissolves during the third week of use. The
company's current product has to be removed by a physician. However, a change in weaving
configuration gives this product the same dissolving time as the competitor's. When can the company's
new suture be marketed?



A. This requires a new 510(k) since significant change in product instructions might

affect efficacy.

B. After submission in a periodic report

C. After reporting clinical studies in an annual report

, D. After submission of labeling change - ✔✔A



A company's competitor is marketing a Class II suture which dissolves during the third week of use. The
company's current product has to be removed by a physician. However, a change in weaving
configuration gives this product the same dissolving time as the competitor's. When can the company's
new suture be marketed?

A. This requires a new 510(k) since significant change in product instructions might effect efficacy

B. After submission in a periodic report

C. After reporting clinical studies in an annual report

D. After submission of labeling change - ✔✔A



A company's supplier of the active drug substance for the company's OTC drug product informs the
company that the supplier will be moving their production of the drug substance from the current plant
to a new manufacturing plant in another state in 6 months. The supplier states that all manufacturing
processes will remain the same and the specifications

will not change. The company intends to qualify the change suitably. How should the company report
the change to FDA?

A. The change only needs to be reported in an annual report because the company will qualify the
change and the supplier said the process and specification won't change

B. The change should be reported in a pre-approval supplement (e.g., CBE, CBE-30 or full pre-approval
supplement) because it is a change to the drug substance manufacturing location

C. The change does not have to be reported because it is an OTC drug

D. Not enough information - ✔✔B?



A defective product was released into distribution and has caused patient injuries. The patients were
treated in a local hospital and may suffer further reversible medical consequences as a result of the
defective product. If this product is recalled from the market, which of the following recall classifications
would most likely be assigned?

A. Class I

B. Class II

C. Class III

D. Class IV - ✔✔B

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller hov. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $8.99. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

77254 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$8.99
  • (0)
  Add to cart